Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
    • Report a Problem
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
    • MIS Systems
    • Online Data Verification
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > News & Updates > Regulatory Updates > Drugs > Notification: Applications for Registration of Multiple Strength and Volume Drugs (Pharmaceutical) on Form-5F

Notification: Applications for Registration of Multiple Strength and Volume Drugs (Pharmaceutical) on Form-5F

Ijaz Mustafa Drugs, Notifications June 15, 2023June 16, 2023

Drug Regulatory Authority of Pakistan, on the recommendations of the Registration Board has issued guidance for submitting applications for registration of pharmaceutical product with multiple strengths and different fill volumes. The Notification issued in this regard is as under:-

notification_fill_volume_2Download

Share this:

  • Twitter
  • Facebook
  • ← Notification: Application on Form-5F (CTD) for Extension in the Contract Manufacturing Permission of Drugs.
  • Rapid Alert; Drug Product: Falsified Ciproxin 500mg Tablets identified in the Market →
  • DRAP at a Glance
    • What We Do?
    • Vision & Mission
    • CEO’s Message
  • Organization
    • Organizational Structure
    • Divisions
    • Policy Board
    • Members of Authority
    • Information and Transparency
    • Strategic Plan
  • Legislation
    • Acts
    • Rules
    • Regulations
    • SROs
    • Notifications
  • Boards and Committees
    • Central Licensing Board
    • Registration Board
    • Medical Devices Board
    • Enlistment Evaluation Committee
    • Clinical Studies Committee
    • Pharmacovigilance RAE Committee
    • Committee on Advertisements
  • Quality Management System
    • Quality Policy
    • Management Reviews
  • Drugs
  • Medical Devices
  • Alternative Medicines
  • Controlled Substances
  • Licensing and Inspections
  • Clinical Trials
  • Pharmacovigilance
  • Advertisements
  • General

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem